Mountain Valley MD Holdings Inc. announced the advancement of its patented Quicksome sublingual delivery platform for compounded peptide applications on Friday [1, 2].
The development represents a strategic move to provide a differentiated delivery solution in the compounded peptide market. By shifting away from traditional administration methods, the company aims to capture a larger share of the evolving marketplace across North and South America [1].
Headquartered in Toronto, the company said it has completed initial formulation work across multiple peptides [1]. One of the primary focuses of this early work includes BPC-157, a peptide often used in compounding applications [1, 2].
The Quicksome platform is designed to facilitate sublingual delivery, which allows substances to be absorbed through the tissues of the mouth. This method typically bypasses the digestive system, potentially offering a more efficient alternative to other administration routes in the compounded peptide sector [1, 2].
Mountain Valley MD is positioning the technology as a specialized tool for providers and patients seeking alternatives to injectable or oral peptides. The company said it intends to leverage its patented technology to establish a competitive edge within the Western Hemisphere's medical compounding landscape [1].
“Mountain Valley MD reported initial formulation work across multiple peptides, including BPC-157.”
The advancement of sublingual delivery for peptides like BPC-157 suggests a shift toward non-invasive administration in the compounding pharmacy sector. If successful, the Quicksome platform could reduce patient reliance on injections, potentially increasing the adoption of peptide therapies across North and South America by lowering the barrier to entry for administration.
